MELISSA KOONCE: Open Payments
NPI 1811415540 · BLYTHEVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,845 in 92 payments from 29 companies in 2025. Trend: 2023 $1,598 · 2024 $1,600 · 2025 $1,845
Food & beverage: $1,570Education: $275
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $277 |
| Incyte Corporation | 8 | $196 |
| Gilead Sciences, Inc. | 3 | $129 |
| Lilly USA, LLC | 5 | $121 |
| Janssen Biotech, Inc. | 5 | $112 |
| AstraZeneca Pharmaceuticals LP | 6 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| PUMA BIOTECHNOLOGY, INC. | 5 | $82 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Ipsen Biopharmaceuticals, Inc | 4 | $65 |
Products named: KISQALI, Trodelvy, ENHERTU, NERLYNX, Fabhalta, LIBTAYO, Onivyde, VENCLEXTA.
Industry payments across AR — which companies pay providers there.
